Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes

Virginia M. Klimek, Emily K. Dolezal, Michael T. Tees, Sean M. Devlin, Karen Stein, Alejandro Romero, Stephen D. Nimer

Research output: Contribution to journalArticle

22 Scopus citations

Abstract

We retrospectively assessed morphologic and cytogenetic responses to 5-azacytidine and decitabine in a cohort of 42 adult therapy-related myelodysplastic syndromes (tMDS) patients treated at Memorial Sloan-Kettering Cancer Center and in 2 industry-sponsored decitabine trials (D0007 and DACO-020). The overall response rate (complete remission. +. marrow CR. +. hematologic improvement) was 38%, including 6 patients with complete remission (14%), 6 with marrow CR with or without hematologic improvement (14%), and 4 with hematologic improvement alone (10%). We conclude that DNA methyltransferase inhibitors showed activity in tMDS that is roughly comparable to that seen in de novo MDS.

Original languageEnglish (US)
Pages (from-to)1093-1097
Number of pages5
JournalLeukemia Research
Volume36
Issue number9
DOIs
StatePublished - Sep 1 2012
Externally publishedYes

Keywords

  • 5-Azacytidine
  • Decitabine
  • Leukemia
  • Therapy-related cancer

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes'. Together they form a unique fingerprint.

  • Cite this

    Klimek, V. M., Dolezal, E. K., Tees, M. T., Devlin, S. M., Stein, K., Romero, A., & Nimer, S. D. (2012). Efficacy of hypomethylating agents in therapy-related myelodysplastic syndromes. Leukemia Research, 36(9), 1093-1097. https://doi.org/10.1016/j.leukres.2012.04.025